Ketamine FDA - Search News

FDA approves Johnson & Johnson's nasal spray for depression

Hosted on MSN · 4h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

CNN on MSN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Fox Business · 1d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

3don MSN

Research indicates recreational ketamine use is on the rise

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

J&J’s ketamine-based drug approved as standalone treatment

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Ketamine-Induced Uropathy: What Urologists Need to Know

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results